The NPM1 mutant defines AML irrespective of blast count

Abstract excerpt

NPM1-mutated acute myeloid leukemia (AML) accounts for about 30%–35% of newly diagnosed cases in adults (50%–60% of all AML with normal karyotype1) and it is characterized by distinctive clinico-pathological and molecular features.2 For this reason, NPM1-mutated AML is now recognized as a distinct entity in both the International Consensus Classification (ICC)3 and the fifth revision of the World Health...